By the time you read this, Pfizer Inc. will be close to beginning distribution of its COVID-19 vaccine.
The scientific and medical community knows more now than it did at the beginning of the pandemic, and more data always is forthcoming. We will be better equipped to continue facing this in 2021.
With the year’s end, we present the State of the Industry report, where we asked our readers to weigh in on several topics, including physician burnout. In the survey results, 63.4% of respondents reported feeling symptoms of burnout (examples included exhaustion, reduced personal efficacy, and feelings of negativity or cynicism toward work). Further, 61.2% of respondents reported experiencing decreased career satisfaction.
In her presentation at the recent American College of Obstetricians and Gynecologists’ Annual Virtual Conference, Denise Jamieson, MD, MPH, reminded the audience that self-care, grace, and compassion are even more important now. “Everyone is under more stress at home and at work than what we are used to,” she said.
As you will see in the editorial from Editor-in-Chief Catherine Y. Spong, MD, this year has been particularly productive for Contemporary OB/GYN. We have so many people to thank, including Spong; our editorial board members, and peer reviewers. We also want to thank former board member Sharon T. Phelan, MD, for her keen insights, and long-time editorial consultant Judith M. Orvos, ELS, whose editorial prowess has helped this magazine be where it is today.
Take care of you and yours during this holiday season, and let’s look forward to 2021.
__
Mike Hennessy, Sr.
Chairman and Founder, MJH Life Sciences
Severe maternal morbidity linked to mental health risks post-delivery
April 26th 2024A recent study revealed that severe maternal morbidity during pregnancy increases the likelihood of mental health hospitalizations or emergency department visits up to 13 years post-delivery, emphasizing the need for mental health screening.
Read More
FDA approves updated label for Biktarvy against HIV-1
April 26th 2024Gilead Sciences has announced FDA approval of an updated Biktarvy label, showcasing safety and efficacy data from a phase 1b trial, positioning it as a pivotal treatment option for pregnant individuals with HIV-1 and suppressed viral load.
Read More
No link found between antenatal corticosteroids and child neurodevelopment
April 25th 2024A recent study found no link between antenatal corticosteroid administration and adverse neurodevelopmental outcomes in children aged 6 years or older, offering reassurance for late preterm delivery practices.
Read More